Natural occurrence of NS5B inhibitor resistance-associated variants in Brazilian patients infected with HCV or HCV and HIV

Resistance-associated variants (RAVs) represent a challenge to the success of new HCV therapies. The aim of this study was to describe the prevalence of naturally occurring NS5B RAVs in Brazilian direct acting antivirals (DAA)-na < ve patients infected with HCV genotype 1, or co-infected with HIV. Patient enrollment and sample collection were performed between 2011 and 2013. Using Sanger-based sequencing, 244 sequences were obtained. RAVs detected in HCV-1a sequences were V321A (1.6 %), M414V (1.3 %), A421V (21.4-23.7 %), A421G (1.3 %) and Y448H (1.3 %); and in HCV-1b sequences were L159F (16.1 %), C316N (7.1-16.3 %) and A421V (3.2-6.3 %). Understanding the real RAVs scenario in patients is fundamental to establishing the most effective therapeutic strategy and in minimizing the risks for their selection.

URI

https://observatorio.fm.usp.br/handle/OPI/18836

Referências

Aissa LJ, 2014, J MED VIROL, V86, P1350
Andre-Garnier E, 2016, ANTIVIR THER, DOI [10.3851/IMP3053, DOI 10.3851/IMP3053]
Patino-Galindo JA, 2016, ANTIMICROB AGENTS CH, V60, P2402, DOI 10.1128/AAC.02776-15
Bartels DJ, 2013, J VIROL, V87, P1544, DOI 10.1128/JVI.02294-12
Castilho MCB, 2011, MEM I OSWALDO CRUZ, V106, P968, DOI 10.1590/S0074-02762011000800011
Campiotto S, 2005, BRAZ J MED BIOL RES, V38, P41, DOI 10.1590/S0100-879X2005000100007
Donaldson EF, 2015, HEPATOLOGY, V61, P56, DOI 10.1002/hep.27375
Eltahla AA, 2015, VIRUSES-BASEL, V7, P5206, DOI 10.3390/v7102868
Everson GT, 2016, LIVER INT, V36, P189, DOI 10.1111/liv.12964
Feld JJ, 2014, SEMIN LIVER DIS, V34, P37, DOI 10.1055/s-0034-1371009
Franco S, 2013, J CLIN VIROL, V58, P726, DOI 10.1016/j.jcv.2013.09.022
Gamal N, 2015, DRUG TODAY, V51, P303, DOI 10.1358/dot.2015.51.5.2332992
Gane EJ, 2013, NEW ENGL J MED, V368, P34, DOI 10.1056/NEJMoa1208953
Gaudieri S, 2009, HEPATOLOGY, V49, P1069, DOI 10.1002/hep.22773
Gower E, 2014, J HEPATOL, V61, pS45, DOI 10.1016/j.jhep.2014.07.027
Hajarizadeh B, 2013, NAT REV GASTRO HEPAT, V10, P553, DOI 10.1038/nrgastro.2013.107
Halfon P, 2012, LIVER INT, V32, P79, DOI 10.1111/j.1478-3231.2011.02716.x
Hall T.A., 1999, NUCL ACIDS S SER, V41, P95, DOI 10.1021/BK-1999-0734.CH008
Hedskog C, 2015, J VIRAL HEPATITIS, V22, P871, DOI 10.1111/jvh.12405
Ito J, 2016, HEPATOL RES
Lawitz E, 2015, ANN NY ACAD SCI, V1358, P56, DOI 10.1111/nyas.12832
Lawitz E, 2013, J HEPATOL, V59, P18, DOI 10.1016/j.jhep.2013.02.009
Legrand-Abravanel F, 2009, ANTIVIR THER, V14, P723
Nguyen LT, 2016, ANTIVIR THER, V21, P447, DOI 10.3851/IMP3025
Lontok E, 2015, HEPATOLOGY, V62, P1623, DOI 10.1002/hep.27934
Ludmerer SW, 2005, ANTIMICROB AGENTS CH, V49, P2059, DOI 10.1128/AAC.49.5.2059-2069.2005
McQuaid Thomas, 2015, J Clin Transl Hepatol, V3, P27, DOI 10.14218/JCTH.2014.00041
Morsica G, 2009, JAIDS-J ACQ IMM DEF, V51, P574, DOI 10.1097/QAI.0b013e3181add592
Pawlotsky JM, 2015, GASTROENTEROLOGY, V148, P468, DOI 10.1053/j.gastro.2015.01.002
Pereira LMMB, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-60
Rockstroh JK, 2015, LIVER INT, V35, P51, DOI 10.1111/liv.12721
Sulkowski Mark S, 2003, Clin Liver Dis, V7, P179, DOI 10.1016/S1089-3261(02)00074-0
Svarovskaia ES, 2016, J INFECT DIS, V213, P1240, DOI 10.1093/infdis/jiv564
Svarovskaia ES, 2014, CLIN INFECT DIS, V59, P1666, DOI 10.1093/cid/ciu697
Tamura K, 2013, MOL BIOL EVOL, V30, P2725, DOI 10.1093/molbev/mst197
Weber R, 2006, ARCH INTERN MED, V166, P1632

Coleções

Artigos e Materiais de Revistas Científicas - FM/MGT
Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/07
Artigos e Materiais de Revistas Científicas - LIM/52
Artigos e Materiais de Revistas Científicas - ODS/03

Página do item completo